HUTCHMED (China) Ltd
HCM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001648257
No open-market purchases or sales by HUTCHMED (China) Ltd insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $46.5M in total; no superinvestor holds it.
Other share classesHMDCF
Q1 2023 vs. Q4 2022
How the institutions holding HUTCHMED (China) Ltd changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 84 | 71 | −13 |
| Shares | 27.7M | 24.6M | −3.07M (−11.1%) |
| Value | $413.3M | $320.6M | −$92.7M (−22.4%) |
New holders (8)
Institutions that held HUTCHMED (China) Ltd at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Abn Amro Investment Solutions | 99,704 | $1.30M | 0.03% |
| Rock Creek Group, LP | 75,000 | $976.5K | 0.13% |
| Marshall Wace, LLP | 24,063 | $313.3K | 0.00% |
| Two Sigma Investments, LP | 18,800 | $244.8K | 0.00% |
| JustInvest LLC | 10,075 | $131.2K | 0.00% |
| Robeco Institutional Asset Management B.V. | 884 | $11.5K | 0.00% |
| Ronald Blue Trust, Inc. | 271 | $4.00K | 0.00% |
| Cutler Group LP | 300 | $3.00K | 0.00% |
Sold out (21)
Institutions that held HUTCHMED (China) Ltd at the end of Q4 2022 and filed for Q1 2023 without it.